MET and hepatocellular carcinoma: The development of single-chain bispecific diabodies targeting c-MET and PD-1 for solid tumors has yielded notable effects, particularly in suppressing HGF/c-MET signaling, migration, and invasion of c-MET+ lung cancer and HCC cell lines such as A549 and MHCC-97H, respectively.